Literature DB >> 2991106

A carrier-protein receptor is not a prerequisite for avid hepatic elimination of highly bound compounds: a study of propranolol elimination by the isolated perfused rat liver.

D B Jones, M S Ching, R A Smallwood, D J Morgan.   

Abstract

The highly efficient hepatic extraction of propranolol by the isolated perfused rat liver does not diminish when albumin binding is increased from 30 to 75%. One possible explanation of this insensitivity of propranolol uptake to changes in albumin binding is the mediation of uptake of bound ligand by an albumin receptor on the hepatocyte as postulated for oleate, taurocholic acid and rose bengal. To test this hypothesis, the hepatic extraction of propranolol was studied in the isolated perfused rat liver using alpha 1-acid glycoprotein, which lacks a hepatocyte receptor, as the carrier protein in the perfusate rather than albumin. Livers were perfused with a medium containing propranolol (4 microM) and varying concentrations of alpha 1-acid glycoprotein (0 to 25 microM). Hepatic extraction of propranolol was very high (0.990 +/- 0.006; mean +/- S.D.) and did not alter significantly despite an increase in bound fraction from 0.2 to 0.8, thus closely paralleling the findings when albumin is the carrier protein. This result indicates that bound propranolol is efficiently cleared by the liver, presumably by a "free intermediate" mechanism, in the absence of a specific carrier-protein receptor on the hepatocyte. This study does not, therefore, support the albumin receptor hypothesis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2991106     DOI: 10.1002/hep.1840050411

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Optimal experimental design for precise estimation of the parameters of the axial dispersion model of hepatic elimination.

Authors:  C H Chou; L Aarons; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

2.  Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.

Authors:  Kiyomi Ito; J Brian Houston
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

3.  Axial tissue diffusion can account for the disparity between current models of hepatic elimination for lipophilic drugs.

Authors:  L P Rivory; M S Roberts; S M Pond
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

4.  Lack of linear correlation between hepatic ligand uptake rate and unbound ligand concentration does not necessarily imply receptor-mediated uptake.

Authors:  R H Smallwood; D J Morgan; G W Mihaly; R A Smallwood
Journal:  J Pharmacokinet Biopharm       Date:  1988-08

Review 5.  The influence of binding to albumin and alpha 1-acid glycoprotein on the clearance of drugs by the liver.

Authors:  D K Meijer; P Van der Sluijs
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

6.  Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.

Authors:  Kiyomi Ito; J Brian Houston
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

7.  Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination?

Authors:  Jasleen K Sodhi; Hong-Jaan Wang; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2020-04-17       Impact factor: 3.922

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.